Brazil moves to notification pathway for Class II devices

Brazil eliminates a premarket approval pathway, instead allowing for premarket notification.

Previously, Brazil has had a “Cadastro” pathway to register Class II medical devices and IVDs. This pathway required more extensive documentation (like a technical dossier) for Class II and higher-risk Class I devices. However, on September 18, 2020, the Brazilian regulatory agency, National Health Surveillance Agency (ANVISA), eliminated the Cadastro pathway.

This change means that Class I and Class II devices will now solely fall under the “Notificação” pathway. The Notificação pathway is a pure notification process; it does not entail ANVISA approval in order to market a device. Device manufacturers should still have documentation available for review by ANVISA in the case of an audit, but the documentation does not have to be submitted prior to marketing. ANVISA’s intent in de-regulating lower-risk devices is to have more agency resources available to focus on higher-risk devices.

You can view the Resolution from ANVISA at this link (text in Portuguese):

Keep up with our other posts on international regulatory bodies here: ROW Tag

About the author

Amy enjoys researching and writing about developments in medical technology and how that intersects with US law. She received her J.D. from the University of Florida Levin College of Law in 2020 and now works as a Regulatory Associate for SoftwareCPR®, a general-purpose regulatory consulting firm that is recognized globally for their expertise with standards and national regulations pertaining to medical device, mobile medical app, and HealthIT software.

What’s New

FDA:  Exemptions, Variances, and Alternate Forms of Adverse Event Reporting for Medical Devices

Manufacturers, importers, and user facilities can request an exemption or variance from any or all of the medical device reporting requirements in 21 CFR Part 803.  Read more:

Corporate Office

15148 Springview St
Tampa, FL 33624
Partners located in the US (CA, FL, MA, MN) and Italy.